Skip to content

Predictors of Contrast-induced Acute Renal Injury in Patients With Acute Coronary Syndrome

Predictors of Contrast-Induced Acute Kidney Injury in Patients With Acute Coronary Syndrome

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07294911
Acronym
PC-AKI-ACS
Enrollment
88
Registered
2025-12-19
Start date
2024-11-02
Completion date
2025-09-02
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Contrast-Induced Acute Kidney Injury

Keywords

Contrast-induced nephropathy, Contrast-induced acute kidney injury, Acute coronary syndrome, Percutaneous coronary intervention, STEMI, NSTEMI, Risk factors, Predictors, Renal dysfunction, CI-AKI

Brief summary

This observational study aims to identify predictors of contrast-induced acute kidney injury (CI-AKI) in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Clinical, laboratory, and procedural factors will be analyzed to determine their association with the development of CI-AKI. The findings may help improve risk stratification and preventive strategies in this high-risk population.

Detailed description

This prospective observational study investigates predictors of contrast-induced acute kidney injury (CI-AKI) among patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). The study was conducted from November 2024 to June 2025 at a tertiary cardiac center. Patients with ACS who underwent coronary angiography or PCI were enrolled consecutively. Clinical characteristics, laboratory parameters, hydration status, use of nephrotoxic drugs, and type and volume of contrast media were recorded. Serum creatinine levels were measured before and 48-72 hours after contrast exposure, and CI-AKI was defined according to KDIGO criteria. The primary objective is to identify independent predictors of CI-AKI using multivariate analysis. Secondary objectives include evaluation of short-term outcomes, such as in-hospital complications and renal function recovery at 90 days. The results are expected to improve understanding of CI-AKI risk in real-world ACS patients and to support preventive strategies in interventional cardiology.

Interventions

Data collected from routine clinical care to evaluate predictors of contrast-induced acute kidney injury after PCI. No intervention applied.

Sponsors

Karaganda Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Age ≥ 18 years Diagnosis of acute coronary syndrome (STEMI or NSTEMI) confirmed by clinical, ECG, and laboratory findings Undergoing coronary angiography or percutaneous coronary intervention with intravascular contrast administration Provided informed consent to participate in the study Availability of baseline and follow-up serum creatinine values

Exclusion criteria

Known chronic kidney disease stage 4 or 5 (eGFR \< 30 mL/min/1.73 m²) or on dialysis Hemodynamic instability not related to acute coronary syndrome (e.g., septic shock) Exposure to intravenous contrast within the previous 7 days Use of nephrotoxic drugs (e.g., aminoglycosides, amphotericin B) within 72 hours prior to contrast exposure Active infection or inflammatory disease affecting renal function Pregnancy or breastfeeding Refusal or inability to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Change in serum creatinine at 90 days90 days after contrast exposureChange in serum creatinine level compared to baseline at 90-day follow-up after contrast exposure, to evaluate renal function recovery or persistent impairment.
Incidence of Contrast-Induced Acute Kidney Injury (CI-AKI)Within 72 hours after contrast exposureOccurrence of contrast-induced acute kidney injury (CI-AKI) defined as an increase in serum creatinine of ≥0.3 mg/dL (≥26.5 µmol/L) or ≥50% from baseline within 48-72 hours after exposure to iodinated contrast media, according to KDIGO criteria.

Secondary

MeasureTime frameDescription
Changes in plasma TIMP-2 concentration2 hours after contrast exposureAssessment of urinary TIMP-2 levels 2 hours after contrast exposure to detect early markers of renal tubular injury

Countries

Kazakhstan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026